Bismuth Subsalicylate in Prevention of Travelers' Diarrhea
common.study.values.description
“Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea”
The purpose of this study is to determine if the use of prophylactic bismuth subsalicylate (BSS) has an effect on the acquisition of travelers' diarrhea (TD) or antimicrobial resistance (AMR) genes in fecal samples among international travelers who departed from the United States to South East Asia, South Central Asia, or Africa. Our hypotheses will be tested using a double-blinded, placebo controlled randomized clinical trial with participants from a pre-travel health clinic in the United States.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - Bismuth subsalicylate
We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.
Drug - Placebo Oral Tablet
Placebo manufactured to mimic pepto bismol
participant.views.study.view.additional
participant.views.study.view.scientific-title
Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea and Impact on Acquisition of Gut Antimicrobial Resistance Genes
common.study.values.clinical-trial-id
NCT03535272
participant.views.study.view.id
YerQ2d
